论文部分内容阅读
目的 总结肿瘤合并心血管疾病患者的临床特点, 分析脑利钠肽( BNP) 、纤溶酶原激活物抑制剂-1 (PAI-1)及心钠素(ANP)与肿瘤患者心血管风险的关系.方法 收集2012 年8 月 ~2016 年7 月贵阳中医学院第一附属医院恶性肿瘤患者120 例, 运用ELISA法检测BNP、 PAI-1 及ANP含量.运用WHO/ISH心血管风险预测图评估10 年心血管风险率.分析BNP、 PAI-1 及ANP水平和肿瘤患者心血管危险的关系.结果 本研究中BNP和PAI-1 中位组的心血管风险均高于低位组, ANP低位组其心血管事件的发生率较高; 与无心血管病史相比较, 有心血管病史的组别, 其 BNP、 PAI -1 显著升高, ANP显著降低.在 Spearman 相关分析中, BNP 与心血管病史显著相关, 与 PAI -1 关系密切, 与血压相关. PAI-1 与BNP和 ANP 密切正相关, 与心血管风险率和心血管疾病史相关. PAI -1 与癌抗原 199 (CA199)显著相关、与癌胚抗原(CEA)相关; ANP与癌抗原125 (CA125)相关.结论 BNP、 PAI -1 和ANP水平不仅与心血管风险率显著相关, 还与肿瘤标志物 CA199 显著相关, 可以作为肿瘤患者心血管风险预测的候选指标.“,”Objective To summary clinical characteristics of cancer patients complicated with cardiovascular diseases and analyze the relationships between brain natriuretic peptide (BNP), plasminogen activator inhibitor-1 (PAI-1), atrial natriuretic peptide (ANP) and cardiovascular risk. Methods 120 patients with pulmonary or intestinal cancer in our hospital during the period from August 2012 to July 2016 were collected. The level of BNP, PAI-1 and ANP were tested by ELISA. The prevalence of cardio-vascular risk within ten years was evaluated with WHO/ISH cardiovascular risk prediction chart. Results The cardiovascular risks in patients with middle level of BNP and PAI-1 were higher than those in patients with low level of BNP and PAI-1. The prevalence of cardiovascular disease in patients with low level of ANP was high. BNP, PAI-1 level were higher and ANP level was lower in pa-tients with cardiovascular disease compared with patients without cardiovascular diseases. Spearman correlation analysis showed that BNP was significantly correlated with cardiovascular disease, was closely correlated with PAI-1 and was correlated with blood pres-sure. There was a remarkable positive correlation between PAI-1 and BNP, ANP. PAI-1 was also correlated with cardiovascular risk and cardiovascular disease history. PAI-1 was significantly positively correlated with CA199 and was correlated with CEA. ANP was correlated with CA125. Conclusion BNP, PAI-1 and ANP can be potential indicators for predicting cardiovascular disease risk in cancer patients.